2024-10-22 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis

### 1. Performance Comparison with S&P 500

Regeneron Pharmaceuticals Inc (REGN) has accumulated **84.89%** return, lagging behind the S&P 500 (VOO) which has gained **136.39%**. This puts REGN at a **-51.5%** cumulative return difference compared to the S&P 500. This performance places REGN in the **26.27th percentile** of its historical performance range against the S&P 500.

**Company Overview:** Regeneron Pharmaceuticals Inc is a biotechnology company that develops and commercializes life-saving medicines for serious diseases.

### 2. Recent Price Movements

* **Closing Price:** $968.03
* **5-Day Moving Average:** $986.68
* **20-Day Moving Average:** $1014.65
* **60-Day Moving Average:** $1100.32

The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a potential downward trend in the short to medium term.

### 3. Technical Indicators

* **RSI:** 24.23 - Indicates oversold conditions, suggesting potential for a rebound.
* **PPO:** -0.15 - Indicates bearish momentum.
* **Delta_Previous_Relative_Divergence:** -11.62 - Shows a recent decline in relative divergence, implying short-term downward pressure.
* **Expected Return:** 0.0% -  Expected long-term (2+ years) return, assuming a buy and hold strategy, is estimated to be in line with the S&P 500.

### 4. Recent Earnings and Outlook

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report for the quarter ending August 1st, 2024, showed an EPS of **13.25**, beating analyst expectations. Revenue came in at **3.55 Billion Dollars**, slightly surpassing estimates as well. This strong performance indicates a positive trend in the company's financial health.

### 5. News and Recent Issues

* **Recent Market Outlook:**  
    * Regeneron faces potential competition in the market with other companies developing similar treatments.
    *  The company's focus on developing innovative treatments for serious diseases remains promising.
* **Analyst Opinions:**
    *  Most analysts maintain a "buy" rating on REGN, citing its strong pipeline of potential therapies.
    *  There are concerns over the company's dependence on a few key products and its ability to maintain market share.
* **Performance Highlights:**
    *  REGN has shown consistent revenue growth in recent quarters, indicating a healthy business model.
    *  The company's recent focus on expanding its product portfolio has generated positive investor sentiment.

**FINBOLD** reports a positive outlook for REGN, highlighting its strong financial position and the potential of its innovative therapies. However, the report also acknowledges potential competitive pressures and the need for continued investment in research and development.

### 6. Overall Analysis

Regeneron Pharmaceuticals Inc (REGN) is a promising biotechnology company with a strong track record of developing innovative treatments. Despite its recent underperformance compared to the S&P 500, the company's robust financial health and ongoing product development efforts suggest potential for future growth. However, investors should consider potential market competition and the company's dependence on a few key products. Technical indicators suggest a potential for a rebound, but it remains important to monitor market developments and analyst sentiment. 

### 7. Report Summary

Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company with a strong financial position and a pipeline of innovative therapies. Although the stock has lagged behind the S&P 500 recently, the company's robust financial performance and ongoing product development efforts suggest potential for future growth. The recent earnings beat and positive analyst sentiment indicate a positive outlook. However, investors should be aware of potential market competition and the company's dependence on a few key products. Technical indicators suggest a potential for a rebound, but it remains important to monitor market developments and analyst sentiment. 
